Evaluation of Renin Level and Some Hormones in Patients with Polycystic Ovarian Syndrome
Article Sidebar
Main Article Content
Abstract
Polycystic Ovarian Syndrome (PCOS) is one of the most frequent gynecological endocrinopathy that occurs in premenopausal females. This study aimed to investigate the relationship between PCOS and Renin Angiotensin Aldosteron system, by measuring the levels of renin, ACE, Kallikren5, FSH and LH in follicular and luteal phase, in addition to evaluating the level of kallikrein 5, which belongs to the kallikrein-kinin system associated with the renin system. The renin-angiotensin system (RAS) is well known as regulator of electrolytes and blood pressure. Renin is previously considered a major enzyme in this system. The study included 90 blood samples for married women of childbearing age between (18-45) years. These samples included 70 samples for women with polycystic ovary syndrome, which were divided into two groups (35 samples in each one), the first was withdrawn in the follicular phase, named PA, and the second in the luteal phase of the menstrual cycle named PB. As for the remaining 20 samples, they represented the control group of healthy women, which were also divided into two groups (CA and CB) as happened with the patient group. In this study, the levels of serum Renin, ACE, LH, FSH and Kallikren5 were evaluated in PCOS patients and compared with the control group in both phases. The results were analyzed by T-Test and ROC. There were no significant differences between patients and the control group in terms of ACE activity or FSH (P>0.05). The results demonstrated that LH, Renin, and Kallikren5 were higher in patient group in both phases (P<0.05). Renin Angiotensin system was affected by PCOS.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1. Zeng, X., Xie, Y. Jie, Liu, Y. Ting, Long, S. Lian, & Mo, Z. Cheng. (2020). Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clinical Chimia Acta, 502, 214–221.
2. Liqaa S. Baqer, Mutaz S. Ahmeid, & Amena H. Al-Obaidi. (2023). Evaluation the Effect of Metformin on Hormones serum levels in women with Polycystic Ovary Syndrome. Tikrit Journal of Pure Science, 22(9), 1–5.
3. Bertoldo, M. J., Caldwell, A. S. L., Riepsamen, A. H., Lin, D., Gonzalez, M. B., Robker, R. L., Ledger, W. L., Gilchrist, R. B., Handelsman, D. J., & Walters, K. A. (2019). A hyperandrogenic environment causes intrinsic defects that are detrimental to follicular dynamics in a PCOS mouse model. Endocrinology, 160(3), 699–715.
4. Shannon, M., & Wang, Y. (2012). Polycystic ovary syndrome: a common but often unrecognized condition. Journal of midwifery & women’s health, 57(3), 221-230.
5. Xu, Y., & Qiao, J. (2022). Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): a review of literature. Journal of healthcare engineering, 14, 1-13.
6. Louwers, Y. V., & Laven, J. S. (2020). Characteristics of polycystic ovary syndrome throughout life. Therapeutic Advances in Reproductive Health, (14)1-9
7. Murri, Insenser, Fernández-Durán, San-Millán, Luque-Ramírez, & Escobar-Morreale, (2018). Non-targeted profiling of circulating microRNAs in women with polycystic ovary syndrome (PCOS): effects of obesity and sex hormones, Metabolism, 86, 49-60.
8. Ożegowska, K., Bartkowiak-Wieczorek, J., Bogacz, A., Seremak-Mrozikiewicz, A., Duleba, A. J., & Pawelczyk, L. (2020). Relationship between adipocytokines and angiotensin converting enzyme gene insertion/deletion polymorphism in lean women with and without polycystic ovary syndrome. Gynecological Endocrinology, 36(6), 496–500.
9. Sheik, R. (2015). Awareness of obesity as a risk factor for polycystic ovary syndrome. Journal of Pharmaceutical Sciences and Research, 7(7), 471.
10. Ajmal N, Khan SZ, Shaikh R. (2019) Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article. Eur J Obstet Gynecol Reprod Biology X; 3:100060.
11. Kiseli, M.; Gürsoy, A. Y., and Caglar, G. S. (2016). Insulin Resistance in Polycystic Ovary Syndrome. PARIPEX-Indian Journal of Research, 4(6).
12. Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millán S, Sánchez-Corona J. (2015) The renin-angiotensin system meets the hallmarks of cancer. JRAAS - J Renin-Angiotensin-Aldosterone Syst.;16(2):227–33.
13. Bekassy Z, Lopatko Fagerström I, Bader M, Karpman D. (2022). Crosstalk between the renin–angiotensin, complement and kallikrein–kinin systems in inflammation. Nat Rev Immunol.;22(7):411–28.
14. Reis FM, Bouissou DR, Pereira VM, Camargos AF, Dos Reis AM, Santos RA. (2011). Angiotensin-(1-7), its receptor Mas, and the angiotensin-converting enzyme type 2 are expressed in the human ovary. Fertil Steril. 95(1):176–81.
15. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem [Internet]. 2005;280(15):14628–35.
16. Shaw JLV, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53(8):1423–32.
17. Strati A, Zavridou M, Bournakis E, Mastoraki S, Lianidou E. (2019). Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer. Analyst.;144(22):6671–80.
18. Gangestad SW, Thornhill R, Garver-Apgar CE. (2005). Adaptations to ovulation: Implications for sexual and social behavior. Curr Dir Psychol Sci.;14(6):312–6.
19. Marwa Ghazi Rifatt, & Saleh M Rahim. (2023). Relationship between serum Prostate Specific Antigen (PSA) in women with polycystic ovary syndrome and some reproductive hormones in Kirkuk city. Tikrit Journal of Pure Science, 22(11), 34-39.
20. Armanini D, Bordin L, Donà G, Sabbadin C, Bakdounes L, Ragazzi E, et al. (2012). Polycystic ovary syndrome: Implications of measurement of plasma aldosterone, renin activity and progesterone. Steroids [Internet]. 77(6):655–8.
21. Saadia Z. (2020). Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese Women. Med Arch (Sarajevo, Bosnia Herzegovina). 74(4):289–93.
22. Khmil M, Khmil S, Marushchak M. (2020). Hormone imbalance in women with infertility caused by polycystic ovary syndrome: Is there a connection with body mass index? Maced J Med Sci. 8:731–7.
23. Alphan Z, Berberoglu Z, Gorar S, Candan Z, Aktas A, Aral Y, et al. (2013). Increased total renin levels but not angiotensin-converting enzyme activity in obese patients with polycystic ovary syndrome. Med Princ Pract.;22(5):475–9.
24. Arefi S, Mottaghi S, Sharifi AM. (2013) Studying the correlation of renin-angiotensin-system (RAS) components and insulin resistance in polycystic ovary syndrome (PCOs). Gynecol Endocrinol.;29(5):470–3.
25. Jaatinen TA, Matinlauri I, Anttila L, Koskinen P, Erkkola R, Irjala K. (1995). Serum total renin is elevated in women with polycystic ovarian syndrome. Fertil Steril.;63(5):1000–4. 26. Chidambaram, Mala; Duncan, John A.; Lai, Vesta S.; Cattran, Daniel C.; Floras, John S.; Scholey, James W.; Miller, Judith A. (2002). Variation in the Renin Angiotensin System throughout the Normal Menstrual Cycle. Journal of the American Society of Nephrology 13(2): p 446-452.
27. Schmaier, A. H. (2003). The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 285(1), R1-R13.